Vaccination against hepatitis a and b in patients with hiv
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Patients coinfected with HIV and viral hepatitis A or B are at increased risk for liver-related morbidity and mortality. Although vaccination is safe and effective in the general population, hepatitis A virus and hepatitis B virus transmission may continue in high-risk populations because vaccine response rates lag behind those seen in healthy populations. Poor immune response to vaccine, atypical markers of prior exposure, and difficulty reaching those at risk underlie the challenges facing clinicians and their HIV-infected patients.
- Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2004, vol 16. Atlanta: US Department of Health and Human Services, CDC; 2005.
- Centers for Disease Control and Prevention: Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002, 51:1–52.
- Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290. CrossRef
- Law WP, Duncombe CJ, Mahanontharit A, et al.: Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004, 18:1169–1177. CrossRef
- Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E: Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol 2000, 95:1316–1322. CrossRef
- Shire NJ, Rouster SD, Rajicic N, Sherman KE: Occult hepatitis B in HIV-infected patients. J Acquir Immune De.c Syndr 2004, 36:869–875. CrossRef
- Dimitrakopoulos A, Takou A, Haida A, et al.: The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infect 2000, 40:127–131. CrossRef
- Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, et al.: Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterology 2003, 50:2093–2097.
- Bodsworth N, Donovan B, Nightingale BN: The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989, 160:577–582.
- Hadler SC, Judson FN, O’Malley PM, et al.: Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunode efciency virus infection. J Infect Dis 1991, 163:454–459.
- Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492–497. CrossRef
- Thio CL, Seaberg EC, Skolasky R, Jr, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921–1926. CrossRef
- Bessesen M, Ives D, Condreay L, et al.: Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 28:1032–1035.
- Centers for Disease Control and Prevention: Recommended adult immunization schedule—United States, October 2005-September 2006. MMWR 2005, 54:Q1–Q4.
- Masur H, Kaplan JE, Holmes KK: Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002, 137:435–478.
- Santagostino E, Gringeri A, Rocino A, et al.: Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994, 72:508–510.
- Hess G, Clemens R, Bienzle U, et al.: Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995, 46:40–42. CrossRef
- Tilzey AJ, Palmer SJ, Harrington C, O’Doherty MJ: Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996, 14:1039–1041. CrossRef
- Neilsen GA, Bodsworth NJ, Watts N: Response to hepatitis A vaccination in human immunodeficiency virusinfected and-uninfected homosexual men. J Infect Dis 1997, 176:1064–1067. CrossRef
- Wallace MR, Brandt CJ, Earhart KC, et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004, 39:1207–1213. CrossRef
- Valdez H, Smith KY, Landay A, et al.: Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000, 14:11–21. CrossRef
- Kemper CA, Haubrich R, Frank I, et al.: Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003, 187:1327–1331. CrossRef
- Weissman S, Feucht C, Yarmohammadi H: Response to hepatitis A vaccination in HIV-positive patients [poster]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco: Foundation for Retrovirology and Human Health; 2004:375. Poster 830.
- Shire NJ, Welge JA, Sherman KE: Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis. Vaccine 2006, 24:272–279. Several studies have reported response rates to hepatitis A vaccine in HIV-infected patients approaching those in healthy volunteers; however, other studies have yielded a significantly abrogated rate of response in those with HIV. This random effects meta-analysis calculated an overall response rate approximating 64% by intention-to-treat analysis, underscoring the necessity of developing adjuvant immune-boosters or other methods for improving response in those with compromised immune systems. CrossRef
- Overton ET, Sungkanuparph S, Powderly WG, et al.: Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41:1045–1048. CrossRef
- Gandhi RT, Wurcel A, Lee H, et al.: Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435–1441. CrossRef
- Fonseca MO, Pang LW, de Paula Cavalheiro N, et al.: Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902–2908. This double-blinded, controlled, randomized trial of HBV vaccine response rates in those with HIV demonstrated that response can be improved by doubling the primary dose of vaccine but that this effect is only seen in patients with relatively well-preserved immune function (CD4+ > 350). CrossRef
- Rey D, Krantz V, Partisani M, et al.: Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000, 18:1161–1165. CrossRef
- Sasaki MG, Foccacia R, de Messias-Reason IJ: Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003, 21:4545–4549. CrossRef
- Ahuja TS, Kumar S, Mansoury H, et al.: Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int 2005, 67:1136–1141. CrossRef
- Valdez H, Mitsuyasu R, Landay A, et al.: Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003, 187:320–325. CrossRef
- Bienzle U, Gunther M, Neuhaus R, et al.: Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38:811–819.
- Cooper CL, Davis HL, Angel JB, et al.: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473–1479. Cooper et al. showed a statistically significant improvement in response rate to vaccine against HBV in HIV-positive patients with CPG 7909 and double dose of vaccine. At 12 months, 100% of those in the adjuvant group had achieved protective levels of antibody (versus 63% of controls). CrossRef
- Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40:1–25.
- Taylor LE, Lai A, Schwartzapfel B, et al.: Analyzing the efficacy of standard hepatitis A and B vaccination schedules in HIV/HCV co-infected patients [poster]. 10th Conference on Retroviruses and Opportunistic Infections. Boston: Foundation for Retrovirology and Human Health; 2003:338. Poster 826.
- Vaccination against hepatitis a and b in patients with hiv
Current Hepatitis Reports
Volume 5, Issue 2 , pp 63-67
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links